Prostate Cancer - Results from #140

Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. December 28, 2022

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer. December 28, 2022

Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry. December 28, 2022

Performance of multiparametric prostate magnetic resonance imaging validated by targeted and systematic transperineal biopsies. December 28, 2022

Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial. December 28, 2022

Long Term Results of a Phase III Randomized Prospective Trial of Erectile Tissue Sparing IMRT for Men with Clinically Localized Prostate Cancer. December 27, 2022

Prognostic Impact and Clinical Implications of Unfavorable Upgrading in Low-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy: Results of a Single Tertiary Referral Center. December 27, 2022

IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. December 27, 2022

Mindfulness-based stress reduction for men on active surveillance for prostate cancer and their spouses: Design and methodology of a randomized controlled trial. December 27, 2022

Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer-A Prospective Cohort Study. December 27, 2022

Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts. December 26, 2022

Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance. December 26, 2022

Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. December 26, 2022

Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer. December 26, 2022

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide. December 26, 2022

Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. December 23, 2022

Network analysis of depression in prostate cancer patients: Implications for assessment and treatment. December 23, 2022

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy. December 23, 2022

Is 18F-FDG PET needed to assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis. December 23, 2022

Should Transperineal Prostate Biopsy Be the Standard of Care? December 23, 2022

Page 8 of 1276

email news signup